CellRev

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐀𝐠𝐠𝐫𝐞𝐆𝐮𝐚𝐫𝐝? 𝑂𝑛𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑎𝑛𝑦 𝑞𝑢𝑒𝑠𝑡𝑖𝑜𝑛𝑠 𝑡ℎ𝑎𝑡 𝑤𝑒 𝑔𝑒𝑡 𝑎𝑠𝑘𝑒𝑑 𝑟𝑒𝑔𝑢𝑙𝑎𝑟𝑙𝑦. AggreGuard is a proprietary blend of bacterially derived wildtype enzymes, selected to facilitate extracellular matrix component digestion without affecting cells. 𝐖𝐡𝐚𝐭 𝐜𝐞𝐥𝐥 𝐭𝐲𝐩𝐞𝐬 𝐚𝐧𝐝 𝐦𝐢𝐜𝐫𝐨𝐜𝐚𝐫𝐫𝐢𝐞𝐫𝐬 𝐚𝐫𝐞 𝐀𝐠𝐠𝐫𝐞𝐆𝐮𝐚𝐫𝐝™ 𝐜𝐨𝐦𝐩𝐚𝐭𝐢𝐛𝐥𝐞 𝐰𝐢𝐭𝐡? We have tested AggreGuard™ with VERO cells, iPSCs, muscle myoblasts, and fibroblasts. We foresee that AggreGuard™ has a wide range of biocompatibility but the dose will be dependent on the cell type as well as the microcarrier pairing. 𝐈𝐬 𝐀𝐠𝐠𝐫𝐞𝐆𝐮𝐚𝐫𝐝™ 𝐥𝐢𝐤𝐞 𝐛𝐮𝐥𝐤 𝐝𝐞𝐭𝐚𝐜𝐡𝐦𝐞𝐧𝐭 𝐞𝐧𝐳𝐲𝐦𝐞 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬? No. AggreGuard™ was not formulated to be used as a bulk detachment reagent. 𝐖𝐢𝐥𝐥 𝐭𝐡𝐢𝐬 𝐚𝐟𝐟𝐞𝐜𝐭 𝐨𝐮𝐫 𝐢𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧/𝐭𝐫𝐚𝐧𝐬𝐟𝐞𝐜𝐭𝐢𝐨𝐧 𝐰𝐨𝐫𝐤𝐟𝐥𝐨𝐰? AggreGuard™ should not have any effect. The enzymatic cocktail half-life is ~18h, allowing for a window of low-to-null activity. We recommend testing dose-response based effects on infection/transfection experiments. 𝐇𝐨𝐰 𝐝𝐨 𝐰𝐞 𝐚𝐝𝐝 𝐀𝐠𝐠𝐫𝐞𝐆𝐮𝐚𝐫𝐝™ 𝐝𝐮𝐫𝐢𝐧𝐠 𝐚 𝐛𝐚𝐭𝐜𝐡 𝐫𝐮𝐧? A concentrated bolus addition at the experimental determined timepoints will suffice for batch runs. Fed-batch runs allow for AggreGuard™ integration during media feed/removal strategies. You can find all of our FAQs in our brochure which can be downloaded via the link in the comments.

Except for hematopoietic-derived cells, most cells isolated from animals are naturally adherent. In vivo, adherent cells interact with their surrounding environment and with each other in order to remain viable and exercise their specific function. Indeed, the intracellular signalling cascades that influence the cells’ morphology, growth, phenotype and final fate are governed by the cells’ cross-talks with the extracellular matrix and by cell-to-cell interactions. Similarly, in vitro they require a “support” to attach to, or each other, for maintaining viability & proliferate, otherwise growth-arrest and anoikis take place. Suspension-adapted cells have their place in bioprocessing. However, they will not replace adherent cell culture. We simply need to get much better at the latter. Our co-founder and CSO, Martina Miotto, PhD, has shared her thoughts. Link in the comments. Need to optimise your adherent cell culture workflows or establish a new scalable process? Speak with us on enquiry@cellrev.co.uk

Biopharma has used microcarriers as a workhorse since the 1960s in dynamic culture (i.e., spinner flasks, stirred tank bioreactors) for biologics production, utilising the surface area-to-volume and mixing advantages over planar culture. The adoption of microcarriers is reported throughout industry as well as academia for cell and gene therapies, new generations of biologics, including emerging fields such as cellular agriculture. A data driven approach will determine if a planar bioprocess - old or new - can be adopted to microcarrier-based systems when technical, cost and time aspects are considered. As always, the governing question should be: “Does this make sense?” Will microcarriers be useful to all bioprocess development routes? Per example, if you have cells which readily grow in single cell suspensions or aggregates – the answer is: No. When evaluating microcarriers, a first step is to determine basic biocompatibility between your cell type and microcarrier types to find a good pairing to promote cell adhesion, proliferation and overall bioprocess efficiency. The biocompatibility will be dependent on microcarrier type (plastic vs. biopolymer microcarrier), surface chemistry and surface charge as well as media formulation. Typically the biocompatibility is done in multiwell plates formats or high-throughput systems to find best-fit solutions. Cell phenotype and good cell biology knowledge will factor into the above: primary cells, stem cells and immortalised commercial cell lines require different cell culture conditions. Evaluating microcarriers as a suitable platform requires a careful thematic consideration on the process development goals: (i) What is the amount and frequency of cells required - millions (106) or billions (109) of cells? (ii) The characterisation of the biological model (i.e., metabolism, phenotype stability) as changes can occur in transition from planar to microcarrier culture. (iii) Cost and time investment: internal investment in upskilling, protocol development and new laboratory kit, or outsourcing development? Curious about microcarriers and process design and want to learn more? Or are you just curious about CellRev and our solutions? Please reach out. #CellRev #microcarriers #bioprocess #spinnerflasks #stirredtankbioreactors #biomanufacturing

As a Phd student in 2017, Martina Miotto, PhD first discovered the ability to gently detach adherent cells from surfaces. CellRev's technology has developed a lot since those early days, but Martina's vision of seeing scientific discoveries applied to make a real world impact remains unchanged. "In 2017, I was a student solving my own technical challenge." "In 2024, I am immensely proud to be able to help others solve their own technical challenges with CellRev solutions. Seeing Livit ACE launch fills me with great pride and I have nothing but gratitude for all of those who have played a role in making my dream a reality." Martina now leads our innovation strategy with further solutions in the pipeline to solve aggregation, clumping, clogging, and cell detachment challenges in cell culture processes. Discover our current solutions for yourself at www.cellrev.co.uk

Inducible pluripotent stem cells (iPSCs) have the potential to differentiate into any cell type in the body, providing selective control for tissue formation. The impact of iPSC-based technology has been creating numerous advances in the fields of regenerative medicine; cell and gene therapies; as well as related fields such as cellular agriculture.   iPSCs require scalable and translatable cell expansion platforms which address the challenges faced by microcarrier and aggregate based culture approaches – critical for enabling future discovery and manufacturing. CellRev aims to provide solutions to these challenges.   In March 2024, CellRev and Getinge launched the Livit ACE (link below), a disruptive adherent cell expansion platform powered by Continuase™. https://lnkd.in/eCMb3U3z   We are already working on a biomanufacturing solution for human iPSCs on the Livit ACE platform. Interested in our bioprocess capability, protocol development or how to integrate our proprietary media additives into your existing workflows? Contact us on enquiry@cellrev.co.uk to discuss #hiPSCs #celltherapy #regenerativemedicine

400 Applications. 60 Pitches. 20 Companies. CellRev are very excited to announce that they are 1 of 20 companies selected to be a part of this years BioTools Innovator program. This is THE life science tools and technology accelerator so to be awarded a place is testament to the innovative approach we take to improving cell culture process efficiency. It's a really exciting time for the company with our first two products in market and commercial traction building quickly. It's all about growth from this point onwards. Announcement here > https://lnkd.in/dFDVpgXd It's also a privilege to represent our beloved region on the international stage. #celltherapy #lifesciences #cellmanufacturing #IAmAnInnovator

Launching a market-first continuous bioprocessing platform took time, perseverance, and a lot of 'breaking down barriers', a CellRev company value. We couldn't be prouder to finally see Livit ACE available on the market. A platform capable of speeding up development times, reducing cost per dose, and enabling mass-market access to the next evolution of cell therapies. Our team reflected on some of the major milestones in the journey. _______________________________ Need a more efficient adherent cell expansion platform? Contact the team to discuss your requirements on enquiry@cellrev.co.uk or download the brochure here - https://lnkd.in/eCMb3U3z Getinge #celltherapy #biomanufacturing #cellculture #bioprocessing

Do you use Microcarriers? Microcarrier-based cultures are a popular approach with many advantages, such as their high surface area per volume ratio, scalability, versatility, and integration with existing systems. Our Bioprocess Engineer Travis Kemp, takes us through the process of taking microcarriers from spinner flasks into stirred tank reactors. Article here > https://lnkd.in/e9uHs8bp In this piece, Travis covers: ➡ Microcarrier seeding approaches ➡ Operational challenges and considerations ➡ Media addition and trouble shooting What would you add? CellRev have developed significant expertise in Microcarrier process development and optimisation. Get in touch at enquiry@cellrev.co.uk to discuss how we can assist your process development efforts.

Cell and Gene Therapy in 2040. Have you read the PA Consulting report compiled by Simon Burnell, Paolo Siciliano and team? It's a fascinating read highlighting four alternative views of C&GT in 2024. Link here > https://lnkd.in/eRyw2bpR We know which version of this world we want to live in. CellRev believe that access is in the process. There is an extremely healthy pipeline of treatments progressing through clinical trials, however, manufacturing remains inherently inefficient. We focus our efforts on transforming manufacturing efficiency to create a world where ground-breaking treatments are readily available and no longer cost prohibitive. In this world, C&GTs are first-line treatments; not last. Reach out to us at enquiry@cellrev.co.uk to discover how we can develop or optimise your cell culture process with our proprietary solutions.

Harsh joined CellRev over 2 years ago, and during that time he has predominantly focused on development of the technology underpinning our recent launch, Livit ACE. It's with great pride that he now oversees this product as Senior Product Manager. 📖 Read what he has to say about bringing Livit ACE to market -> https://lnkd.in/d5KYtmJa Interested in scalable adherent cell culture? Download the Livit ACE brochure now - https://lnkd.in/eCMb3U3z